Patent · US Active

Targeted disruption of T cell receptor genes using talens

US9937207B2 · kind B2 · utility

35Cited by
34References
13Claims
0Family size

Assignees

Inventors

Key dates

Filing dateMar 20, 2014
Grant dateApr 10, 2018
Priority date—
Expiry dateDec 13, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2740/16043
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed herein are methods and compositions for modifying TCR genes, using nucleases (zinc finger nucleases or TAL nucleases) to modify TCR genes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.